Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Last updated: March 24, 2026
Sponsor: Hannover Medical School
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

blood samples

Clinical Study ID

NCT03798860
DSA-2018
  • All Genders

Study Summary

Single-arm, prospective observational study

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • all patients after lung transplantation with detection of donor-specific antibodies

Exclusion

Exclusion Criteria:

  • none

Study Design

Total Participants: 340
Treatment Group(s): 1
Primary Treatment: blood samples
Phase:
Study Start date:
October 01, 2018
Estimated Completion Date:
December 31, 2025

Study Description

This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.

Connect with a study center

  • Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery

    Hannover,
    Germany

    Site Not Available

  • Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery

    Hanover,
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.